Aslam N, Lo SW, Sikafi R, et al. A review of the therapeutic management of ulcerative colitis. Therap Adv Gastroenterol. 2022;15:17562848221138160. https://doi.org/10.1177/17562848221138160.

Article  PubMed  PubMed Central  Google Scholar 

Ye Y, Manne S, Treem WR, et al. Prevalence of inflammatory bowel disease in pediatric and adult populations: recent estimates from large national databases in the United States, 2007–2016. Inflamm Bowel Dis. 2020;26(4):619–25. https://doi.org/10.1093/ibd/izz182.

Article  PubMed  Google Scholar 

Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384–413. https://doi.org/10.14309/ajg.0000000000000152.

Article  PubMed  Google Scholar 

AbbVie Inc. RINVOQ® (upadacitinib) Highlights of Prescribing Information 2023. https://www.rxabbvie.com/pdf/rinvoq_pi.pdf. Accessed 9 Feb 2024.

Bristol Myers Squibb Company. ZEPOSIA® (ozanimod) Highlights of Prescribing Information 2023. https://packageinserts.bms.com/pi/pi_zeposia.pdf. Accessed 9 Feb 2024.

Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158(5):1450–61. https://doi.org/10.1053/j.gastro.2020.01.006.

Article  PubMed  Google Scholar 

Abbott. Abbott's Humira® (adalimumab) receives U.S. FDA approval for the treatment of adult patients with moderate to severe ulcerative colitis 2012. https://abbott.mediaroom.com/2012-09-28-Abbotts-HUMIRA-adalimumab-Receives-U-S-FDA-Approval-for-the-Treatment-of-Adult-Patients-with-Moderate-to-Severe-Ulcerative-Colitis#:~:text=Abbott's%20HUMIRA%C2%AE%20(adalimumab)%20Receives,Ulcerative%20Colitis%20%2D%20Sep%2028%2C%202012. Accessed 9 Feb 2024.

Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201–14. https://doi.org/10.1056/NEJMoa1900750.

Article  CAS  PubMed  Google Scholar 

US Food and Drug Administration. BLA 761044/S-003 BLA 125261/S-152 Supplement Approval 2019. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/761044Orig1s003,%20125261Orig1s152ltr.pdf. Accessed 12 Feb 2024.

Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60(6):780–7. https://doi.org/10.1136/gut.2010.221127.

Article  CAS  PubMed  Google Scholar 

Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(2):257 e1-265. https://doi.org/10.1053/j.gastro.2011.10.032.

Article  CAS  Google Scholar 

Armuzzi A, DiBonaventura MD, Tarallo M, et al. Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe. PLoS ONE. 2020;15(1): e0227914. https://doi.org/10.1371/journal.pone.0227914.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sah J, Teeple A, Muser E, et al. Treatment persistence and maintenance dose titration among ulcerative colitis patients on biologics: a pooled study of three United States claim databases. Curr Med Res Opin. 2022;38(7):1093–101. https://doi.org/10.1080/03007995.2022.2071041.

Article  CAS  PubMed  Google Scholar 

Khan S, Rupniewska E, Neighbors M, et al. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: a systematic review. J Clin Pharm Ther. 2019;44(4):495–507. https://doi.org/10.1111/jcpt.12830.

Article  PubMed  Google Scholar 

Chen C, Hartzema AG, Xiao H, et al. Real-world pattern of biologic use in patients with inflammatory bowel disease: treatment persistence, switching, and importance of concurrent immunosuppressive therapy. Inflamm Bowel Dis. 2019;25(8):1417–27. https://doi.org/10.1093/ibd/izz001.

Article  PubMed  Google Scholar 

Goss Sawhney T, Dobes A, O’Charoen S. Real-world persistency for inflammatory bowel disease biologics using patient registry data. Crohns Colitis 360. 2023;5(4):otad051. https://doi.org/10.1093/crocol/otad051.

Article  PubMed  PubMed Central  Google Scholar 

Janssen Pharmaceutical Companies. STELARA® (ustekinumab) Highlights of Prescribing Information 2022. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf. Accessed 24 Jan 2024.

Zhdanava M, Ding Z, Manceur AM, et al. Treatment persistence among bio-naïve patients with Crohn’s disease initiated on ustekinumab or adalimumab. Curr Med Res Opin. 2023;39(4):533–43. https://doi.org/10.1080/03007995.2023.2178148.

Article  CAS  PubMed  Google Scholar 

Zhdanava M, Zhao R, Manceur AM, et al. Persistence and other treatment patterns among bio-experienced patients with Crohn’s disease initiated on ustekinumab or adalimumab. J Manag Care Spec Pharm. 2023;29(8):907–16. https://doi.org/10.18553/jmcp.2023.29.8.907.

Article  PubMed  PubMed Central  Google Scholar 

Xu C, Ferrante SA, Fitzgerald T, et al. Inconsistencies in the days supply values reported in pharmacy claims databases for biologics with long maintenance intervals. J Manag Care Spec Pharm. 2023;29(1):90–100. https://doi.org/10.18553/jmcp.2023.29.1.90.

Article  PubMed  Google Scholar 

AbbVie Inc. HUMIRA® (adalimumab) Highlights of Prescribing Information 2021. https://www.rxabbvie.com/pdf/humira.pdf. Accessed 24 Jan 2024.

Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009;38(6):1228–34. https://doi.org/10.1080/03610910902859574.

Article  Google Scholar 

Fitzgerald T, Zhdanava M, Pilon D, et al. Response to the Letter to the Editor: Long-term psoriasis control with guselkumab, adalimumab, secukinumab, or ixekizumab in the USA. Dermatol Ther (Heidelb). 2023;13(11):2917–23. https://doi.org/10.1007/s13555-023-01017-8.

Article  PubMed  Google Scholar 

Patel H, Lissoos T, Rubin DT. Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn’s disease in the United States. PLoS ONE. 2017;12(4): e0175099. https://doi.org/10.1371/journal.pone.0175099.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Luttropp K, Dalén J, Svedbom A, et al. Real-world patient experience of switching biologic treatment in inflammatory arthritis and ulcerative colitis—a systematic literature review. Patient Preference Adher. 2020;14:309–20. https://doi.org/10.2147/PPA.S238843.

Article  Google Scholar 

Zhdanava M, Zhao R, Manceur AM, et al. Persistence and dose escalation during maintenance phase and use of nonbiologic medications among patients with ulcerative colitis initiated on ustekinumab in the United States. Crohns Colitis 360. 2023;5(3):otad045. https://doi.org/10.1093/crocol/otad045.

Article  PubMed  PubMed Central  Google Scholar 

Bressler B, Jones J, In TSH, et al. Real-world persistence of ustekinumab in the treatment of inflammatory bowel disease. Adv Ther. 2023;40(10):4421–39. https://doi.org/10.1007/s12325-023-02611-0.

Article  CAS  PubMed  Google Scholar 

Chiappetta MF, Viola A, Mastronardi M, et al. One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy. Expert Opin Biol Ther. 2021;21(11):1483–9. https://doi.org/10.1080/14712598.2021.1981855.

Article  CAS  PubMed  Google Scholar 

Fumery M, Filippi J, Abitbol V, et al. Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study. Aliment Pharmacol Ther. 2021;54(7):944–51. https://doi.org/10.1111/apt.16544.

Article  CAS  PubMed  Google Scholar 

Blesl A, Binder L, Högenauer C, et al. Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world study. Aliment Pharmacol Ther. 2021;54(5):667–77. https://doi.org/10.1111/apt.16478.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pouillon L, Baumann C, Rousseau H, et al. Treatment persistence of infliximab versus adalimumab in ulcerative colitis: a 16-year single-center experience. Inflamm Bowel Dis. 2018;25(5):945–54. https://doi.org/10.1093/ibd/izy322.

Article  Google Scholar 

Hoque S, Puenpatom A, Boccaletti S, et al. Treatment persistence and colectomy-free outcomes in patients with ulcerative colitis receiving golimumab or adalimumab: a UK experience. BMJ Open Gastroenterol. 2020. https://doi.org/10.1136/bmjgast-2020-000476.

Article  PubMed  PubMed Central  Google Scholar 

Zhdanava M, Ding Z, Manceur AM, et al. Long-term persistence and other treatment patterns among bio-naïve patients with Crohn’s disease treated with ustekinumab or adalimumab. Curr Med Res Opin. 2023;39(9):1215–25.